ArticleJournal of translational internal medicine2020
Potential Role of ACE2 in Coronavirus Disease 2019 (COVID-19) Prevention and Management.
Article in Journal of translational internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 82 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
82 citing papers in PubMed, 3 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Performance of Serum Angiotensin-Converting Enzyme in Diagnosing Sarcoidosis and Predicting the Active Status of Sarcoidosis: A Meta-Analysis.Biomolecules · 2022Pooled it
- Serum Krebs von den Lungen-6 for Predicting the Severity of COVID-19 Lung Injury: A Systematic Review and Meta-Analysis.Iranian biomedical journal · 2021Pooled it
- Pooled it
- Investigation of the correlation between serum levels of interleukin-6 and clinical and paraclinical findings in COVID-19 patients.Current therapeutic research, clinical and experimental · 2026Article
- Post-Acute Nasal Expression of ACE2, TMPRSS2, FURIN, and NRP1 in Relation to COVID-19 Severity: A Multicenter Cross-Sectional Study.Diagnostics (Basel, Switzerland) · 2026Article
- Mechanistic evaluation of the in vitro antiviral and anti-inflammatory potential of thyme and licorice herbal preparation.Scientific reports · 2026Article
- Shock prediction with dipeptidyl peptidase-3 and renin (SPiDeR) in hypoxemic patients with COVID-19.Journal of critical care · 2025Article
- Phenotypic switch of vascular smooth muscle cells in COVID-19: Role of cholesterol, calcium, and phosphate.Journal of cellular physiology · 2024Review
- Molecular mechanisms of thalidomide effectiveness on COVID-19 patients explained: ACE2 is a new ΔNp63α target gene.Journal of molecular medicine (Berlin, Germany) · 2024Article
- Article
- A cardiotoxicity-eliminated ACE2 variant as a pan-inhibitor against coronavirus cell invasion.Molecular therapy : the journal of the American Society of Gene Therapy · 2024Article
- A non-enhanced CT-based deep learning diagnostic system for COVID-19 infection at high risk among lung cancer patients.Frontiers in medicine · 2024Article
- The long-term health outcomes, pathophysiological mechanisms and multidisciplinary management of long COVID.Signal transduction and targeted therapy · 2023Review
- Article
- Article
- Role of Angiotensin Converting Enzyme-2 and its modulation in disease: exploring new frontiers.Medicine and pharmacy reports · 2023Review
- ACE2-Inhibitory Effects of Bromelain and Ficin in Colon Cancer Cells.Medicina (Kaunas, Lithuania) · 2023Article
- In Vitro Antiviral Evaluations of ColdmixCurrent issues in molecular biology · 2023Article
- Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study.Infection and drug resistance · 2023Article
- Genetic Variations in the Human Angiotensin-ConvertingEnzyme 2 and Susceptibility to Coronavirus Disease-19.Genetics research · 2023Article
22 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
COVID-19 is the current public health threat all over the world. Unfortunately, there is no specific prevention and treatment strategy for this disease. We aim to explore the potential role of angiotensin-converting enzyme 2 (ACE2) in this regard through this literature review. As a crucial enzyme of renin-angiotensin-aldosterone system (RAAS), ACE2 not only mediates the virus entry but also affects the pathophysiological process of virus-induced acute lung injury (ALI), as well as other organs' damage. As interaction of COVID-19 virus spike and ACE2 is essential for virus infection, COVID-19-specific vaccine based on spike protein, small molecule compound interrupting their interaction, human monoclonal antibody based on receptor-binding domain, and recombinant human ACE2 protein (rhuACE2) have aroused the interests of researchers. Meanwhile, ACE2 could catalyze angiotensin II (Ang II) to form angiotensin 1-7 (Ang 1-7), thus alleviates the harmful effect of Ang II and amplifies the protection effect of Ang1-7. ACE inhibitor and angiotensin II receptor blocker (ARB) have been shown to increase the level of expression of ACE2 and could be potential strategies in protecting lungs, heart, and kidneys. ACE2 plays a very important role in the pathogenesis and pathophysiology of COVID-19 infection. Strategies targeting ACE2 and its ligand, COVID-19 virus spike protein, may provide novel method in the prevention and management of novel coronavirus pneumonia.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.